Children’s cancer breakthrough hopes
TREATMENT CAN NOW BE ADAPTED TO INDIVIDUAL CHILDREN
CHILDREN with brain cancer may be spared gruelling chemotherapy treatment after a breakthrough by Newcastle scientists.
The findings of a large study mean that medics could adapt their treatment for each child with medulloblastoma, the most common type of brain cancer.
The scientists, led by Newcastle University, have been able to identify a chromosome signature which can tell them which children will need intensive, aggressive chemotherapy as treatment.
The study’s findings, published today in The Lancet Oncology, also shows that many youngsters with medulloblastoma could avoid unnecessary doses of chemotherapy and radiotherapy with less toxic side effects.
Currently all patients receive the same treatment.
The news has been welcomed by the parents of Olly McKenna who was diagnosed with medulloblastoma less than a year ago and has battled back to health.
The 12-year-old, from Bill Quay, Gateshead, had surgery for nine hours to remove his aggressive tumour and underwent months of tough radiotherapy and chemotherapy sessions.
His parents Jason and Jill have welcomed the research being undertaken in the North East into the brain cancer which affected their son.
Jill, 44, a superintendent radiographer, said: “It is incredibly important that as much research as possible is done into medulloblastoma so that patients receive the best treatment options.
“Each child currently diagnosed with the condition is given the same treatment and this level of toxicity makes the youngsters very ill – for parents it’s awful watching their child go through that.
“To know that research has identified that therapy should be tailored to each individual child is fantastic as it will mean that children will not be given toxic treatment unnecessarily.
“The most important thing is that children have as few side effects as possible so that they can continue to have a good quality of life during and after treatment.”
Professor Steve Clifford, director of the Northern Institute for Cancer Research at Newcastle University, led the European study with Dr Edward Schwalbe from Northumbria University.
Professor Clifford said: “Our findings provide a new blueprint for the personalisation of treatment in medulloblastoma so that all children are not given the same intensity of therapy.
“This study shows that low-risk patients may receive kinder treatments aimed at reducing toxicity and side effects, while targeting more intensive treatments to the highrisk patients who need it most.
“Medulloblastoma is the most common malignant childhood brain tumour and it is important that we have improved outcomes for patients with this disease.
“Through a greater understanding of brain tumours we hope to increase the cure rate but criti-
cally, for those children who survive, we want to make sure their quality of life is good after treatment.”
The study is part of the largest completed clinical trial of medulloblastoma undertaken across Europe and it is hoped that it will lead to significantly improved outcomes for patients in the future.
Experts identified that children with the cancer can be split into two clinical groups – about half of which are low-risk with close to 100% survival, while the other half are high-risk, with 60% survival.
The study analysed data from a clinical trial of standard-risk medulloblastoma, which ran from 2001-2006, and was partly funded by Cancer Research UK.
The standard-risk patients were children with no recognised risk factors for the disease and who would be expected to have a survival rate of around 80% after five years.
Working with the University of Bonn in Germany, the Newcastle and Northumbria team identified patterns of chromosome gains and losses in medulloblastoma tumours.
The team found a chromosome signature that identifies a group of patients with 100% survival rates, and a high-risk group with just 60% survival.
Dr Ed Schwalbe, senior lecturer in bioinformatics and biostatistics at Northumbria University, said: “In this study, we identified an easily testable chromosome signature that predicts excellent outcomes for children with medulloblastoma.
“Importantly, we also show that this signature works as expected in an independent set of patients.
“Looking forward, we hope that children whose tumours have this signature could be treated less aggressively, reducing the life-long side effects of the gruelling treatments, while maintaining a cure.”
Medulloblastoma is the most common high grade childhood tumour, accounting for 15-20% of all childhood brain tumours.
Current treatment for the cancer is surgery to remove the tumour, followed by radiotherapy and an intensive course of chemotherapy.
Researchers are now working with the European trial group to put the the findings of this study into action in future trials in order to adapt therapy in the future.